Recent Finacing
Recent Raise
Mozart Therapeutics develops bispecific and cytokine-based CD8 regulatory T‑cell modulators, advancing MTX‑101, a KIR‑inhibiting bispecific autoimmune checkpoint inhibitor, from preclinical toward IND and Phase 1 testing for autoimmune diseases.
